{"id":"sg","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":{"setId":"865b3b41-61da-4eba-b00e-6899d812213e","title":"OVAPRIM (SGNRHA AND DOMPERIDONE) INJECTION, SOLUTION [WESTERN CHEMICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adenosine accumulates in tumors and suppresses T cell function through A2A receptor signaling. By blocking A2A receptors, SG (also known as AB928) prevents adenosine-mediated immunosuppression, allowing T cells to mount a more effective anti-tumor response. This mechanism is often combined with checkpoint inhibitors like PD-1/PD-L1 inhibitors to further enhance immune activation.","oneSentence":"SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:25:57.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT07438600","phase":"PHASE2","title":"Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-24","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT07123883","phase":"NA","title":"Dry Needling for Temporomandibular Disorder","status":"COMPLETED","sponsor":"Atlas University","startDate":"2025-07-28","conditions":"TMD/Orofacial Pain, Muscle Spasm","enrollment":40},{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":695},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT05833867","phase":"PHASE1","title":"Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Shilpa Gupta, MD","startDate":"2024-04-01","conditions":"Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma","enrollment":20},{"nctId":"NCT07461610","phase":"","title":"Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03","conditions":"Morbid Obesity","enrollment":50},{"nctId":"NCT07305597","phase":"NA","title":"Effects of Virtual Reality-Assisted Pain Neuroscience Education on Chronic Nonspecific Low Back Pain","status":"RECRUITING","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2026-01-15","conditions":"Chronic Non-Specific Low Back Pain","enrollment":60},{"nctId":"NCT05876780","phase":"PHASE1","title":"A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2022-12-19","conditions":"Limb Girdle Muscular Dystrophy","enrollment":6},{"nctId":"NCT07063212","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer","enrollment":40},{"nctId":"NCT06963905","phase":"PHASE1, PHASE2","title":"Saci Nivo Rela for TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-29","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT06309238","phase":"NA","title":"Intensive Weight Loss Intervention Versus Bariatric Surgery for Adults With Severe and Complex Obesity: the LightBAR Randomised Trial","status":"RECRUITING","sponsor":"Carsten Dirksen","startDate":"2024-05-08","conditions":"Obesity","enrollment":500},{"nctId":"NCT05186974","phase":"PHASE2","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-05-30","conditions":"Non-small Cell Lung Cancer","enrollment":193},{"nctId":"NCT04915014","phase":"NA","title":"Sleeve Gastrectomy With Transit Bipartition(SG+TB) Versus Roux-en-Y Gastric Bypass (RYGB) for Type 3 Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2021-07-23","conditions":"Severe Obesity","enrollment":320},{"nctId":"NCT06614647","phase":"NA","title":"RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-09-15","conditions":"Colorectal Cancer, Quality of Life, Survivorship","enrollment":400},{"nctId":"NCT06926920","phase":"PHASE1, PHASE2","title":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-30","conditions":"Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT03964727","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-10-15","conditions":"Metastatic Solid Tumor","enrollment":223},{"nctId":"NCT07339059","phase":"PHASE2","title":"SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Bindu R Potugari","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":35},{"nctId":"NCT03754699","phase":"NA","title":"Preoperative Education for Less Outpatient Pain After Surgery (PELOPS)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-01-22","conditions":"Outpatient Orthopedic Surgery","enrollment":412},{"nctId":"NCT07367178","phase":"PHASE2","title":"Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT07368543","phase":"PHASE2","title":"Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"Metastatic Breast Cancer","enrollment":216},{"nctId":"NCT04350892","phase":"NA","title":"Cerebrospinal Fluid Biomarkers in Bariatric Surgery","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-10-20","conditions":"Obesity","enrollment":51},{"nctId":"NCT07134556","phase":"PHASE2","title":"Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-03","conditions":"Triple Negative Breast Cancer, PDL-1 Positive","enrollment":25},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT07359404","phase":"PHASE2","title":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","status":"ENROLLING_BY_INVITATION","sponsor":"YING FAN","startDate":"2024-04-01","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05000749","phase":"NA","title":"DBT Skills Groups for Veterans at High Risk for Suicide Attempt","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-04-30","conditions":"Suicide, Attempted","enrollment":156},{"nctId":"NCT06865677","phase":"PHASE2","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-09","conditions":"Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma","enrollment":2},{"nctId":"NCT05633654","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-12-12","conditions":"Triple Negative Breast Cancer","enrollment":1514},{"nctId":"NCT06486441","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Endometrial Cancer","enrollment":640},{"nctId":"NCT07320027","phase":"NA","title":"Acute Impact of Static, Dynamic, and Proprioceptive Exercises on Proprioception, Strength, Balance, and Explosive Power","status":"COMPLETED","sponsor":"Konya Necmettin Erbakan Üniversitesi","startDate":"2025-08-08","conditions":"Neuromuscular Control, Balance, Musculoskeletal Function","enrollment":48},{"nctId":"NCT06263543","phase":"PHASE2","title":"Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC","status":"RECRUITING","sponsor":"Reshma L. Mahtani, D.O.","startDate":"2024-06-17","conditions":"Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":75},{"nctId":"NCT05005039","phase":"","title":"Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-04-20","conditions":"Bariatric Surgery in Postmenopausal Women","enrollment":40},{"nctId":"NCT07299279","phase":"NA","title":"Movement Improves Brain Health and Cognition in Parkinson's Disease","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-09","conditions":"Parkinson Disease","enrollment":150},{"nctId":"NCT07299409","phase":"PHASE2","title":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Nathalie Levasseur","startDate":"2025-12","conditions":"Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer","enrollment":24},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT06728579","phase":"PHASE2","title":"Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-06","conditions":"Breast Cancer Survivor","enrollment":200},{"nctId":"NCT07290075","phase":"","title":"The Relationship Between Olfactory and Gustatory Senses, Hedonic Hunger, and Diet Quality After Bariatric Surgery","status":"COMPLETED","sponsor":"Hanife Köksal","startDate":"2024-01-01","conditions":"Obesity, Taste Disorders, Smell Disorder","enrollment":101},{"nctId":"NCT04863885","phase":"PHASE1, PHASE2","title":"Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-04-30","conditions":"Metastatic Urothelial Carcinoma","enrollment":46},{"nctId":"NCT07271992","phase":"PHASE2","title":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12-15","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06238921","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-12-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT07265440","phase":"NA","title":"Effect of New Specialized Technique Using Effleurage Massage on Striae Gravidarum","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-10-09","conditions":"Striae Gravidarum","enrollment":42},{"nctId":"NCT07263269","phase":"NA","title":"Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in Adults With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mina Kamal Gergis Erian","startDate":"2024-04-06","conditions":"Obesity, Morbid Obesity, Dumping Syndrome","enrollment":200},{"nctId":"NCT05574855","phase":"","title":"Evaluation of Haemodynamic in Neonates Treated With Hypothermia\"","status":"COMPLETED","sponsor":"Princess Anna Mazowiecka Hospital, Warsaw, Poland","startDate":"2021-08-01","conditions":"Hypothermia Neonatal, Haemodynamic Instability, Perinatal Asphyxia","enrollment":113},{"nctId":"NCT07259226","phase":"PHASE2","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer","enrollment":400},{"nctId":"NCT07251868","phase":"","title":"Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-08-01","conditions":"Breast Cancer, Brain Metastases From Breast Cancer, Trop2","enrollment":100},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT05207917","phase":"NA","title":"How Does Bariatric Surgery Affect Social Experiences and Well-being - The BaSES-study","status":"ENROLLING_BY_INVITATION","sponsor":"The Hospital of Vestfold","startDate":"2022-05-12","conditions":"Obesity","enrollment":113},{"nctId":"NCT06081244","phase":"PHASE3","title":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","status":"RECRUITING","sponsor":"West German Study Group","startDate":"2024-10-10","conditions":"Triple Negative Breast Cancer","enrollment":348},{"nctId":"NCT05119907","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-12","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT04794699","phase":"PHASE1","title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2021-04-14","conditions":"Solid Tumor","enrollment":180},{"nctId":"NCT04724018","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan Plus EV in Metastatic UC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-05-20","conditions":"Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter","enrollment":106},{"nctId":"NCT07217418","phase":"NA","title":"Music Therapy and Its Effects on Premenstrual Syndrome (PMS)","status":"COMPLETED","sponsor":"West Chester University of Pennsylvania","startDate":"2024-02-01","conditions":"Premenstrual Syndrome, Menstrual Symptoms","enrollment":20},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT04319198","phase":"PHASE4","title":"Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-08-04","conditions":"Metastatic Solid Tumors","enrollment":25},{"nctId":"NCT06827613","phase":"PHASE1, PHASE2","title":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Marengo Therapeutics, Inc.","startDate":"2025-03-24","conditions":"Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":50},{"nctId":"NCT07187258","phase":"PHASE4","title":"the Use of Tranexamic Acid to Prevent the Bleeding in Bariatric Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Haemorrhage, Bariatric Surgery Candidate","enrollment":132},{"nctId":"NCT05382286","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-25","conditions":"Triple Negative Breast Cancer, PD-L1 Positive","enrollment":443},{"nctId":"NCT07178730","phase":"PHASE3","title":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, Triple-negative Breast Cancer","enrollment":765},{"nctId":"NCT07021170","phase":"PHASE4","title":"Trial Comparing Elan Specialized Bariatric Supplements With Standard Multivitamins in Patients Undergoing Bariatric Procedures","status":"RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2025-06-15","conditions":"Vitamin Deficiencies","enrollment":624},{"nctId":"NCT07021248","phase":"PHASE4","title":"A Randomized Controlled Trial Evaluating the Impact of Procedure-Specific Bariatric Supplements on Micronutrient Status and Vitamin B6 Hypervitaminosis Following Metabolic and Bariatric Surgery","status":"RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2025-06-15","conditions":"Micronutrient Status","enrollment":249},{"nctId":"NCT07172997","phase":"","title":"Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2025-01-01","conditions":"MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD)","enrollment":163},{"nctId":"NCT07162259","phase":"PHASE4","title":"Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yan Xue","startDate":"2025-10-01","conditions":"Breast Neoplasms","enrollment":40},{"nctId":"NCT07040644","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-09","conditions":"Triple Negative Breast Neoplasms","enrollment":150},{"nctId":"NCT05382299","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-20","conditions":"Triple Negative Breast Cancer, PD-L1 Negative","enrollment":623},{"nctId":"NCT07158008","phase":"NA","title":"Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2025-07-31","conditions":"Gastro Esophageal Reflux, Severe Obesity, Bariatric Surgery","enrollment":560},{"nctId":"NCT05961033","phase":"","title":"The Effects of Virtual Reality Based Exercises in Patients With Adhesive Capsulitis","status":"COMPLETED","sponsor":"Kocaeli University","startDate":"2023-09-01","conditions":"Pain, Quality of Life, Range of Motion","enrollment":36},{"nctId":"NCT07151586","phase":"PHASE2","title":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-10","conditions":"Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer","enrollment":260},{"nctId":"NCT06616987","phase":"PHASE2","title":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Yeon Hee Park","startDate":"2025-07-03","conditions":"Breast Cancer Metastatic","enrollment":40},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT06481644","phase":"","title":"Asia Pediatric Intensive Care Epidemiology and Outcomes Study","status":"RECRUITING","sponsor":"KK Women's and Children's Hospital","startDate":"2024-08-01","conditions":"Pediatrics, Intensive Care Unit, Critical Illness","enrollment":10000},{"nctId":"NCT07100639","phase":"","title":"Singapore Population Research on Integrated exposoMe & Early Menopause","status":"NOT_YET_RECRUITING","sponsor":"Institute for Human Development and Potential (IHDP), Singapore","startDate":"2025-08-06","conditions":"Early Menopause","enrollment":400},{"nctId":"NCT07088627","phase":"NA","title":"Performance and Hormonal Responses to Different Training Modalities in Young Weightlifters: A Randomised Controlled Trial","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2021-02-02","conditions":"Weightlifting, Hormone, Young","enrollment":32},{"nctId":"NCT06923826","phase":"PHASE2","title":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-04-15","conditions":"Salivary Gland Cancer, Thyroid Cancer","enrollment":32},{"nctId":"NCT04381832","phase":"PHASE1, PHASE2","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2020-07-07","conditions":"Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms","enrollment":173},{"nctId":"NCT06477419","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in People With Mesothelioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-21","conditions":"Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura","enrollment":33},{"nctId":"NCT06945016","phase":"","title":"Monitoring Nutritional Consequences of Obesity Treatment on Women's Health","status":"RECRUITING","sponsor":"Wageningen University and Research","startDate":"2025-01-28","conditions":"Obesity and Obesity-related Medical Conditions, Bariatric Surgery, Anti-obesity Agents","enrollment":1150},{"nctId":"NCT03908177","phase":"NA","title":"Comparison of Clinical Performance and Safety of Zirconia vs. Titanium Implants: a Multi-national RCT.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Straumann AG","startDate":"2019-09-07","conditions":"Dental Implants, Single-Tooth","enrollment":124},{"nctId":"NCT07046455","phase":"NA","title":"Trop-2 Targeted PET Probes in Advanced TNBC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":20},{"nctId":"NCT06044441","phase":"NA","title":"Evaluation and Implementation Preparation of a Proactive Palliative Care Model (ENABLE-SG)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2023-12-26","conditions":"Neoplasms","enrollment":715},{"nctId":"NCT06200896","phase":"NA","title":"Early Feasibility Study: Assessment of Self-Forming Magnetic Anastomosis Device and Delivery System (SFM) in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post SG (SNAP-PS), or Used to Create a Jejuno-Jejunal (J-J) Anastomosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"GI Windows, Inc.","startDate":"2023-12-12","conditions":"Obesity, Morbid","enrollment":28},{"nctId":"NCT05518487","phase":"PHASE2","title":"COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-02-20","conditions":"COVID-19, Kidney Transplant","enrollment":15},{"nctId":"NCT06665178","phase":"PHASE2","title":"Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-03-31","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT07018427","phase":"","title":"Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-05-01","conditions":"Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":70},{"nctId":"NCT05552001","phase":"PHASE3","title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-05","conditions":"Triple Negative Breast Cancer, Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT06991790","phase":"","title":"Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-01","conditions":"TNBC","enrollment":51},{"nctId":"NCT05089734","phase":"PHASE3","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-11-17","conditions":"Non-Small Cell Lung Cancer","enrollment":603},{"nctId":"NCT06055465","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-02-28","conditions":"Lung Cancer","enrollment":37},{"nctId":"NCT06966141","phase":"","title":"A Real World Study of Sacituzumab Govitecan","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-08-12","conditions":"Breast Cancer Metastatic, Treatment Outcome","enrollment":100},{"nctId":"NCT03371368","phase":"NA","title":"Metabolism and Bariatric Surgery Study","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-10-16","conditions":"Insulin Resistance, Obesity","enrollment":70},{"nctId":"NCT06401824","phase":"PHASE2","title":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2025-04-24","conditions":"NSCLC Stage IV, Brain Metastases, Adult","enrollment":25},{"nctId":"NCT05092399","phase":"","title":"Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-07-01","conditions":"Type2 Diabetes, NAFLD, Obesity","enrollment":21},{"nctId":"NCT06947421","phase":"NA","title":"The Effect of Different Exercises on Craniovertebral Angle in Individuals With Forward Head Posture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bahçeşehir University","startDate":"2025-04-16","conditions":"Forward Head Posture","enrollment":44},{"nctId":"NCT06937398","phase":"","title":"Survey on Patient and Parental Perceptions of EEG-monitoring During Paediatric Anaesthesia Care","status":"RECRUITING","sponsor":"KK Women's and Children's Hospital","startDate":"2022-05-01","conditions":"Survey on Patient and Parental Perceptions of EEG-monitoring During Paediatric Anaesthesia Care","enrollment":400},{"nctId":"NCT01984762","phase":"NA","title":"Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2012-09","conditions":"Obesity, Type 2 Diabetes, Bariatric Surgery","enrollment":134},{"nctId":"NCT06803888","phase":"PHASE4","title":"Bariatric Surgery vs. Semaglutide vs. Tirzepatide","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2025-01-29","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":125},{"nctId":"NCT04329780","phase":"","title":"Retrospective Comparison of Lap and Robotic-Assisted RYGB and SG","status":"COMPLETED","sponsor":"Intuitive Surgical","startDate":"2020-04-01","conditions":"Bariatric Surgery Candidate","enrollment":1872},{"nctId":"NCT06431633","phase":"PHASE3","title":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-02-04","conditions":"Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma","enrollment":129},{"nctId":"NCT06265649","phase":"","title":"Comparison of NOM for ACLD Between Medical and Surgical Ward","status":"RECRUITING","sponsor":"Ospedali Riuniti Trieste","startDate":"2024-01-01","conditions":"Diverticulitis, Colon Disease, Acute Diverticulitis","enrollment":175},{"nctId":"NCT05765864","phase":"","title":"Self-harm Behaviour Among the Most At-risk Adolescents","status":"RECRUITING","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2023-03-23","conditions":"Self-harm, Personality Disorder, Borderline, Epigenetic Disorder","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18023,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trodelvy"],"phase":"marketed","status":"active","brandName":"SG","genericName":"SG","companyName":"Arcus Biosciences, Inc.","companyId":"arcus-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}